CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues		$ 16,868	$ 15,693	$ 45,627	$ 39,859
Expenses:
Research and development	[1]	9,268	8,311	28,190	32,308
Selling, general and administrative	[1]	16,875	16,142	50,673	54,603
Impairment of long-lived assets (non-cash)		1,562		4,513
Restructuring and related expenses			0	0	2,743	[1]
Total expenses		27,705	24,453	83,376	89,654
Loss from operations		(10,837)	(8,760)	(37,749)	(49,795)
Interest expense (non-cash)		(630)	(609)	(1,903)	(1,727)
Interest and other income, net		1,415	1,786	3,977	7,269
Loss before income taxes		(10,052)	(7,583)	(35,675)	(44,253)
Provision for income tax expense		(2,646)	(1,367)	(5,216)	(2,430)
Net loss		(12,698)	(8,950)	(40,891)	(46,683)
Other comprehensive loss:
Net unrealized gain (loss) on available-for-sale investments		72	61	115	(210)
Total comprehensive loss		$ (12,626)	$ (8,889)	$ (40,776)	$ (46,893)
Net loss per share:
Net loss - basic (in dollars per share)		$ (0.26)	$ (0.17)	$ (0.84)	$ (0.81)
Net loss - diluted (in dollars per share)		$ (0.26)	$ (0.17)	$ (0.84)	$ (0.81)
Shares used to compute net loss per share - basic		49,038	52,361	48,690	57,287
Shares used to compute net loss per share - diluted		49,038	52,361	48,690	57,287
Viatris collaboration agreement
Revenues:
Total revenues		$ 16,868	$ 15,687	$ 45,627	$ 39,841
Collaboration revenue
Revenues:
Total revenues			$ 6		$ 18

[1] Amounts include share-based compensation expense as follows: